Companies / Industrials
BA
Boeing
Aerospace & Defense
Aerospace & DefenseAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health32
Growth85
Profitability20
Cash generation6
Balance sheet11
Dilution control40
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)3.9%Revenue growth (FY)34.5%Revenue CAGR (3y)10.3%Gross margin4.8%Operating margin4.8%Net margin2.5%Free cash flow margin-2.1%R&D / revenue4.0%Stock comp / revenue0.5%Net debt / operating cash flow40.31xCurrent ratio1.19Diluted share count change17.8%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $62.3B | $66.6B | $77.8B | $66.5B | $89.5B |
| Gross profit | $3.0B | $3.5B | $7.7B | -$2.0B | $4.3B |
| Operating income | -$2.9B | -$3.5B | -$773M | -$10.7B | $4.3B |
| Net income | -$4.2B | -$4.9B | -$2.2B | -$11.8B | $2.2B |
| Operating cash flow | -$3.4B | $3.5B | $6.0B | -$12.1B | $1.1B |
| Capital expenditure | $980M | $1.2B | $1.5B | $2.2B | $2.9B |
| Free cash flow | -$4.4B | $2.3B | $4.4B | -$14.3B | -$1.9B |
| R&D | $2.2B | $2.9B | $3.4B | $3.8B | $3.6B |
| Stock-based comp | $833M | $725M | $690M | $407M | $426M |
| Dividends | — | — | — | — | $331M |
| Cash | $8.1B | $14.6B | $12.7B | $13.8B | $10.9B |
| Total debt | $57.9B | $56.8B | $52.1B | $53.6B | $53.8B |
| Equity | -$15.0B | -$15.9B | -$17.2B | -$3.9B | $5.5B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.